After obtaining a world-first approval by the UK Government, the low-priced and broadly accessible corticosteroid dexamethasone has received notable attention following groundbreaking data indicating that it can lessen Covid-19 deaths among hospitalised patients. While data supporting dexamethasone’s effectiveness seem clear, the magnitude of its advantage remains modest.

GlobalData considers that further studies of dexamethasone are required to bypass the roadblocks faced by hydroxychloroquine, where significant distinctions in results made it challenging to determine the drug’s role in Covid-19 treatment. Read more here.